NICE recommends Takeda’s Takhzyro for NHS use to prevent hereditary angioedema attacks
September 18, 2019Research and Development, Sales and Marketing NHS, NICE, Takeda, Takhzyro, pharma
UK drug watchdog NICE has announced its final draft guidance recommending Takeda’s subcutaneous injection Takhzyro (Lanadelumab) for use on the …
US, Canada and Australia simultaneously fast-track Keytruda/Lenvima combo for endometrial cancer
September 18, 2019Research and Development, Sales and Marketing Australian Therapeutic Goods Administration, Cancer, FDA, Health Canada, Lenvima, keytruda, pharma
The FDA has acted under a new initiative in collaboration with the Australian Therapeutic Goods Administration (TGA) and Health Canada, …
New agreement gives AstraZeneca full responsibility for Linzess in China
September 18, 2019Research and Development AstraZeneca, IBS-C, Linzess
AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals in China for Linzess (linaclotide), a first-in-class new treatment for patients …
Swiss biotech raises $16m for ‘undelivery mechanism’ in rare liver disease
September 18, 2019Research and Development liver disease, versantis
A new method from Swiss Biotech Versantis promises to give far better immediate care and offer a treatment for a …
Roche bags FDA Breakthrough for Gazyva in lupus nephritis
September 18, 2019Research and Development FDA, Gazyva, Roche, lupus nephritis
The US FDA has granted Breakthrough Therapy Designation to Gazyva (obinutuzumab) for adults with lupus nephritis. The win comes on …
New APPG report on access to cutting edge medicines
September 17, 2019Manufacturing and Production
A new report from the All-Party Parliamentary Groups (APPG) is urging the life science community to work together to speed …
UKRI Chief Executive Sir Mark Walport to step down in 2020
September 17, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing UKRI, appointment, pharma
Sir Mark Walport, Chief Executive of UK Research and Innovation (UKRI), the national funding agency responsible for science and research …
New experimental approach could stop common cold
September 17, 2019Manufacturing and Production, Research and Development
Scientists believe they may have found a way to stop the common cold as instead of attacking the virus directly, …
Acceleron terminates drug candidate following facioscapulohumeral muscular dystrophy failure
September 17, 2019Manufacturing and Production, Research and Development Acceleron, pharma, trial failure
Acceleron Pharma has seen its stock fall by almost 4% after it unveiled new Phase 2 data confirming that its …
Enlarged prostate drug may slow Parkinson’s disease
September 17, 2019Manufacturing and Production, Research and Development Parkinson's, terazosin
A surprising find has led researchers to see that a drug used to treat enlarged prostates may also work as …
Novartis’ Cosentyx has strong Phase 3 interim showing in axial spondyloarthritis
September 17, 2019Manufacturing and Production, Research and Development Cosentyx, Novartis, pharma
Novartis has highlighted new data from its ongoing Phase 3 trial into the efficacy and safety of itsinterleukin-17A inhibitor Cosentyx …
Jerome Carle steps down as Julphar Chief Executive
September 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Chief Executive of Gulf Pharmaceutical Industries, Jerome Carle, is stepping down from his post at the United Arab Emirates drug …
Breaking through limits in lung cancer: Introducing The Lung Ambition Alliance
September 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, Lung Ambition Alliance, lung cancer, oncology, pharma
Patrick Connor, VP and Global Franchise Head, Tumor Drivers and Resistance Mechanisms, at AstraZeneca, discusses his company’s role in the …
Opioid drugmaker Purdue Pharma files for bankruptcy
September 16, 2019Sales and Marketing OxyContin, Purdue Pharma
In the face of thousands of lawsuits in its role in the opioid addiction crisis, Purdue Pharma announced yesterday that …
Aimmune’s peanut allergy therapy recommended for approval by FDA committee
September 16, 2019Sales and Marketing Aimmune, FDA, peanut allergy, pharma
The FDA’s Allergenic Products Advisory Committee (APAC) has recommended the use of Aimmune Therapeutics’ AR101, also known by its proposed …
Lundbeck acquires Alder in $2bn migraine treatment move
September 16, 2019Sales and Marketing Alder, Lundbeck, eptinezumab, migraine
Lundbeck is to buy Alder Biopharmaceuticals for $2 billion enhancing its leading portfolio of brain disease therapies through the acquisition …
Amgen’s Kyprolis + Darzalex combo shows progression-free survival benefit in multiple myeloma
September 16, 2019Research and Development, Sales and Marketing Amgen, Kyrpolis, darzalex, multiple myeloma, pharma
Amgen has revealed new Phase 3 data for the combination of Kyprolis (carfilzomib) and Darzalex (daratumumab) in addition to the …
Novartis announce robust Phase 3 trials for ofatumumab in MS
September 16, 2019Research and Development, Sales and Marketing Aubagio, Novartis, multiple sclerosis
Novartis’ multiple sclerosis candidate has demonstrated strong results in its Phase 3 ASCLEPIOS trials meeting primary endpoints and slashing the …
Multi-study data confirms Ocrevus’ long-term efficacy in reducing disability progression in multiple sclerosis
September 13, 2019Medical Communications, Research and Development ECTRIMS, Ocrevus, Roche, multiple sclerosis, pharma
Roche has taken the opportunity at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference in Stockholm …
Top Ten most popular articles on Pharmafile.com this week
September 13, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
It’s Friday again and time for another rundown of the top most popular articles on Pharmafile.com this week. This past …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
